Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Intrexon Corporation patents


Recent patent applications related to Intrexon Corporation. Intrexon Corporation is listed as an Agent/Assignee. Note: Intrexon Corporation may have other listings under different names/spellings. We're not affiliated with Intrexon Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Intrexon Corporation-related inventors


Modified gram positive bacteria and uses thereof

The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. ... Intrexon Corporation

Polycistronic expression system for bacteria

. . The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium.. . ... Intrexon Corporation

Frataxin expression constructs

The invention provides polynucleotides, vectors and viruses expressing frataxin and methods of treating friedreich's ataxia.. . ... Intrexon Corporation

Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof

The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.. . ... Intrexon Corporation

Methods for dynamic vector assembly of dna cloning vector plasmids

. . A method for using cloning vector plasmids to produce dna molecules, such as transgenes, in a single cloning step. The transgenes can be used for the purpose of gene expression or analysis of gene expression. ... Intrexon Corporation

Method to improve lactococcus preservation

Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a l. ... Intrexon Corporation

Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof

This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. ... Intrexon Corporation

Cd33 specific chimeric antigen receptors

Provided herein are chimeric antigen receptors (cars) for cancer therapy, and more particularly, cars containing a scfv from a cd33 monoclonal antibody. Provided are immune effector cells containing such cars, and methods of treating proliferative disorders such as acute myeloid leukemia (aml), and relapsed or refractory aml.. ... Intrexon Corporation

Mutant receptors and their use in a nuclear receptor-based inducible gene expression system

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. ... Intrexon Corporation

Biological production of multi-carbon compounds from methane

Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (ch4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. ... Intrexon Corporation

Improved therapeutic control of heterodimeric and single chain forms of interleukin-12

The present invention relates to modified forms of il-12. These modified forms of il-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of il-12. ... Intrexon Corporation

Modified forms of pseudomonas exotoxin a

Pseudomonas exotoxin a or “pe” is a 66 kd, highly potent, cytotoxic protein secreted by the bacterium pseudomonas aeruginosa. Various forms of pe have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). ... Intrexon Corporation

Endoplasmic reticulum localization signals

The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. ... Intrexon Corporation

Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. ... Intrexon Corporation

07/06/17 / #20170191027

Methods and compositions for treating disease

The present invention relates to methods and compositions for treating a subject comprising destroying diseased cells in the subject. The methods comprise obtaining a population of cells from a subject and determining the activity of at least one disease marker gene within the population of the obtained cells. ... Intrexon Corporation

06/01/17 / #20170152529

Biological production of multi-carbon compounds from methane

Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (ch4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. ... Intrexon Corporation

06/01/17 / #20170151292

Cryoprotectants for freeze drying of lactic acid bacteria

The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (lab), at different temperatures, whereby the retention of viability of the freeze-dried lab after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular lactic acid bacteria. ... Intrexon Corporation

05/11/17 / #20170128569

Engineered cells expressing multiple immunomodulators and uses thereof

This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (il-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.. ... Intrexon Corporation

04/27/17 / #20170114370

Site-specific serine recombinases and methods of their use

The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attp) or a bacterial genomic recombination attachment site (attb), the second recombination site is attb or attp, and the recombinase is selected from the group consisting of a listeria monocytogenes phage recombinase, a streptococcus pyogenes phage recombinase, a bacillus subtilis phage recombinase, a mycobacterium tuberculosis phage recombinase and a mycobacterium smegmatis phage recombinase, provided that when the first recombination attachment site is attb, the second recombination attachment site is attp and when the first recombination attachment site is attp, the second recombination attachment site is attb. The invention also describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. ... Intrexon Corporation

04/20/17 / #20170107175

Crystalline diacylhydrazine and the use thereof

The present disclosure provides crystalline polymorphic and amorphous forms of (r)-3,5-dimethyl-benzoic acid n-(1-tert-butyl-butyl)-n′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (compound 1) or (s)-3,5-dimethyl-benzoic acid n-(1-tert-butyl-butyl)-n′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (compound 2). The present disclosure further provides compositions comprising crystalline polymorphic and amorphous forms of compound 1 or compound 2 and an excipient, methods of making crystalline polymorphic or amorphous forms of compound 1 or compound 2, and methods of using crystalline polymorphic or amorphous forms of compound 1 or compound 2 to regulate gene expression in a cell or in a subject.. ... Intrexon Corporation

04/13/17 / #20170100475

Induction of mucosal tolerance to antigens

The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism.. ... Intrexon Corporation

04/06/17 / #20170096673

Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. ... Intrexon Corporation

04/06/17 / #20170096672

Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. ... Intrexon Corporation

03/16/17 / #20170073693

Regulatory element for heterologous protein production in the fruiting body of filamentous fungi

The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the agaricus bisporus lectin gene. ... Intrexon Corporation

02/09/17 / #20170037386

Modified forms of pseudomonas exotoxin a

Pseudomonas exotoxin a or “pe” is a 66 kd, highly potent, cytotoxic protein secreted by the bacterium pseudomonas aeruginosa. Various forms of pe have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). ... Intrexon Corporation

01/19/17 / #20170015728

Novel substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. ... Intrexon Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Intrexon Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Intrexon Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###